Valensa Joins Algae Biomass Organization to Drive Innovation In Microalgae Nutraceuticals

5585952d-1835-4493-a102-50053a308b41articleimage.jpg

15 Jun 2017 --- Valensa International has joined the Algae Biomass Organization (ABO), a major trade association for the algae industry, thereby joining the growing ranks of companies and organizations that are becoming part of the ABO to create awareness about microalgae as a sustainable source of human nutrition, animal feed, water treatment services, chemicals, fuels and countless other products. 

“The ABO’s mission is to ‘promote the development of viable commercial markets’ for products derived from Algae. Valensa is a ‘disruptive innovator’ in microalgae-based nutraceuticals, creating safe, sustainable indication-specific solutions for enhanced health. The power of algae-based nutraceuticals is just emerging on the world scene, and the ABO is getting the word out,” C.P. Umasudhan, CEO at Valensa International, tells NutritionInsight.

“We are excited to have industry leader Valensa join the Algae Biomass Organization’s efforts to expand the availability of algae-based products in dozens of markets,” says Matt Carr, executive director of the ABO. “Valensa’s experience commercializing advanced technologies in human health and nutrition are among the most important for an industry that is just beginning show its potential to provide new products, improve global sustainability, and trigger new economic growth.”

Click to EnlargeHeadquartered in Eustis, Florida, Valensa International is a leading designer of science-based, naturally-sourced proprietary blends of ingredients for nutritional supplements and functional foods. Valensa International holds more than 60 US and International Patents for Formulations and Manufacturing (Deep Extract Supercritical CO2 and O2B Peroxidation Blocker stabilization.) 

“Valensa and affiliate Parry Nutraceuticals have been diligently working on expanding the scope of microalgae production technology including controlled race-way cultures, hybrid closed systems and fermentation technology needed to create safe, efficacious, microalgae-based nutraceuticals,” Umasudhan says. 

Valensa’s scientific team specializes in developing clinical research and intellectual property to introduce unique condition-specific formulations. 

“While applications for microalgae are unlimited, Valensa is producing condition specific algae-based products for eye, cardio and joint health. Valensa’s science team is also working on products that will revolutionize the Immune Health category in both nutraceuticals and functional foods. Retailers and consumers are demanding the next generation in immunity care and the future is promising,” Umasudhan tells NutritionInsight.

Additionally, Valensa has completed clinical work, and continues clinical research, to improve the standard of care in the Immune Health category. Several microalgae approaches have already shown great promise, according to Uma. Valensa is currently in the process of defining microalgae strains and commercialization technology to manufacture algae-derived omega 3 fatty acids (EPA, DHA).

“Exclusive algae-based formulations will become the next generation of nutraceuticals to accommodate growing consumer demand for safe, healthy, sustainable-sourced and all-natural products,” says Umasudhan. “We look forward to building the future of sustainable algae with the support of the ABO.”

“The ABO was created with the overwhelming belief that our future needs lie in the development of microalgae. Some microalgae, like Spirulina, were developed to provide high-quality nutrition to the world. Hybrid open and closed water systems in rural areas, with sustainable production, are set to compete with, or surpass, land or ocean based farming in the near future,” Umasudhan says. 

“The application of spirulina, chlorella and haematococcus pluvialis derived astaxanthin have not yet even scratched the surface of their potential for nutraceutical, functional foods, natural colorant and pharmaceuticals. Valensa, and affiliate Parry Nutraceuticals, are also looking to bring the next generation of plant-based, clean, sustainable omega 3’s to the market. Valensa’s core strategy is to conduct clinical trials and license  intellectual property to enable their customers to sell products that are efficacious and differentiated,” Umasudhan concludes.

Related Articles

Nutrition & Health News

Dietary Carotenoids and Vitamin C Inversely Correlate to Lung Cancer Risk, Study Suggests

29 Jun 2017 --- A new study has revealed the protective effects of selected carotenoids and vitamin C against lung cancer risks and growth of a different type of carcinoma cells, with the results showing that when compared to low intake of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene and vitamin C, subjects with highest intake of aforementioned carotenoids and vitamin C demonstrated reduced risk of lung cancer. 

Food Research

Cheers to That: Researchers Create Gut-Friendly Probiotic Beer

29 Jun 2017 --- Beer lovers may soon have a gut-friendly drink to raise a toast to, thanks to the creation of a novel probiotic sour beer by a team of researchers from the National University of Singapore (NUS). This new specialty beer incorporates the probiotic strain Lactobacillus paracasei L26, which was first isolated from human intestines and can neutralize toxins and viruses, as well as regulate the immune system.

Business News

Lonza Receives Regulatory Approval for the Acquisition of Capsugel

29 Jun 2017 --- Lonza has received all regulatory approvals for the proposed acquisition of Capsugel S.A. by Lonza, the company has announced. With all final regulatory approvals in place, Lonza can now complete the transaction, which is expected to close in the next days subject to the satisfaction of customary closing conditions. 

Nutrition & Health News

FSAI Launches Consultation on Vitamin D Supplements for Infants in Ireland

29 Jun 2017 --- The Food Safety Authority of Ireland (FSAI) today announced that it is holding a public consultation on the criteria for 5µg Vitamin D only supplements to be listed as suitable for infants in Ireland. The online consultation started yesterday and will be held until 11 August. FSAI invites caregivers, health professionals, food supplement manufacturers, food businesses and any other interested parties to take part. This consultation is in the form of a survey which can be found on the FSAI website.

Nutrition & Health News

More than Half of Foods Aimed at Children are Unhealthy, Australian Survey Shows

28 Jun 2017 --- New research by Australia’s Obesity Policy Coalition (OPC) has found that more than half of supermarket products marketed at kids are unhealthy. The OPC surveyed 186 packaged foods with cartoons or character promotions designed to attract children and found that 52 percent were classified as unhealthy by the Food Standards Australia New Zealand (FSANZ) Nutrient Profiling Scoring Criterion calculator, which looks at the amount of energy and certain nutrients (e.g. saturated fat, sugars, sodium) present in the food.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-joins-algae-biomass-organization-to-drive-innovation-in-microalgae-nutraceuticals.html